

Ref no: 180120418
From: Commercial
Date: 12/04/18
Subject: Urothelial Cell Cancer

REQUEST

FOI Request re Urothelial Cancer Patients

Please indicate the number of metastatic or locally advanced Urothelial¹ cancer patients treated² by your Trust in the 3 months, December 2017 to February 2018 inclusive.

If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.

	Total number treated (Metastatic/locally advanced Urothelial patients)	If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:	
Total number of metastatic or locally advanced Urothelial cancer (UCC, transitional carcinoma, TCC) patients treated		Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	

Of the metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, December 2017 to February 2018 inclusive, please indicate the number treated with the following therapies.

Therapy	Total number treated (Metastatic/locally advanced Urothelial)	If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has

¹ ICD10 C65, C66, C67, C68; TNM staging for metastatic Urothelial Cancer = Any T, any N, M1; TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0; Please include numbers for:

- any diagnosis of metastatic disease as opposed to patients that present with metastases
- all metastatic sites from a Urothelial primary

² Please indicate the number of patients (excluding clinical trial patients) treated with any active anti-cancer drug treatment.

	patients)	been provided:	
Cisplatin (mono or combination therapy)		Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Carboplatin (mono or combination therapy)		Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Pembrolizumab (Keytruda)		Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Atezolizumab (Tecentriq)		Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	

If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:

¹ ICD10 C65, C66, C67, C68; TNM staging for metastatic Urothelial Cancer = Any T, any N, M1; TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0; Please include numbers for:

- any diagnosis of metastatic disease as opposed to patients that present with metastases
- all metastatic sites from a Urothelial primary

¹ Please indicate the number of patients (excluding clinical trial patients) treated with any active anti-cancer drug treatment

RESPONSE

We cannot supply this information – Clatterbridge are responsible for the delivery of Chemotherapy for Urology cancer patients.